Cellbricks is redefining how biology is created, by specialising in 3D bioprinting, with the aim of improving human health by bringing synthetic organs to reality. This method of 3D printed cell structures – which simulate human tissues and organs – are changing the way drugs are designed. Not only do they overcome the need for animal-based drug testing, they also revolutionise individual medical treatment. Cellbricks is creating products for multiple applications in biomedical research and tissue engineering.


By combining bioinks (the basis of a 3D cell structure), bioprinting (which prints living tissue fast, in high resolution and easy to scale up) and services (such as a tool chain from CAD modeling to cloud services), Cellbricks is enabling researchers to engineer functional human tissues and organ models. This technology is already used by researchers and biologists – making the creation of physiological tissues easy and accessible.


Drug development can take up to a decade, and whilst the real cost of medicine development is a highly-debated subject, figures suggest the cost of creating a market-approved prescription drug from scratch is in the region of $2.5bn.

Cellbricks are enabling biomedical and tissue engineering that could affect drug design on a global scale, which could end animal-based testing and even help develop personalised medical treatments. Founder Lutz Kloke has previously stated that he hopes his company will eventually help end organ transplant shortages.


Cellbricks have no disclosed funding. Their vision is to eventually print patient-specific organs to solve the issue of donor organ shortages.